Context Therapeutics Statistics
Context Therapeutics (6K9) Stock Statistics & Valuation Metrics
Total Valuation
Context Therapeutics has a market cap or net worth of EUR 15.38M. The enterprise value is EUR 9.98M.
- Market Cap
- EUR 15.38M
- Enterprise Value
- EUR 9.98M
Share Statistics
Context Therapeutics has 91,879,170 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 91,879,170
- Owned by Insiders
- 1.35%
- Owned by Institutions
- 16.93%
Financial Efficiency
Context Therapeutics’s return on equity (ROE) is -0.60 and return on invested capital (ROIC) is -65.53%.
- Return on Equity (ROE)
- -0.60
- Return on Assets (ROA)
- -0.53
- Return on Invested Capital (ROIC)
- -65.53%
- Return on Capital Employed (ROCE)
- -0.66
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.41M
- Employee Count
- 15
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Context Therapeutics is -0.41. Context Therapeutics’s PEG ratio is 0.01.
- PE Ratio
- -0.41
- PS Ratio
- 0.00
- PB Ratio
- 0.57
- Price to FCF
- -0.50
- Price to Operating Cash Flow
- -0.52
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Context Therapeutics had revenue of 0 and earned -36.12M in profits. Earnings per share was -0.38.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -39.70M
- Pretax Income
- -36.12M
- Net Income
- -36.12M
- EBITDA
- -36.11M
- Earnings Per Share (EPS)
- -0.38
Cash Flow
In the last 12 months, operating cash flow was -33.97M and capital expenditures -55,749, giving a free cash flow of -34.03M billion.
- Operating Cash Flow
- -33.97M
- Free Cash Flow
- -34.03M
- Free Cash Flow per Share
- -0.36
Dividends & Yields
Context Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -192.59%
- Earnings Yield
- -251.08%
Stock Price Statistics
- Beta
- 0.06
- 52-Week Price Change
- -84.19%
- 50-Day Moving Average
- 0.23
- 200-Day Moving Average
- 1.16
- Relative Strength Index (RSI)
- 42.21
- Average Volume (3m)
- ―
Important Dates
Context Therapeutics upcoming earnings date is Mar 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 24, 2027
- Ex-Dividend Date
- ―
Financial Position
Context Therapeutics as a current ratio of 8.52, with Debt / Equity ratio of 0.19%
- Current Ratio
- 8.52
- Quick Ratio
- 8.52
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.82
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Context Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Context Therapeutics EV to EBITDA ratio is 0.55, with an EV/FCF ratio of 0.74.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.55
- EV to Free Cash Flow
- 0.74
- EV to Operating Cash Flow
- 0.74
Balance Sheet
Context Therapeutics has EUR 42.99M in cash and marketable securities with EUR 244.99K in debt, giving a net cash position of EUR 42.75M billion.
- Cash & Marketable Securities
- EUR 42.99M
- Total Debt
- EUR 244.99K
- Net Cash
- EUR 42.75M
- Net Cash Per Share
- EUR 0.47
- Tangible Book Value Per Share
- EUR 0.40
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Context Therapeutics is EUR 4.48, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 4.48
- Price Target Upside
- 2945.41% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -16.25%
